
|Articles|September 10, 2015
Certara, Paidion Research Form Pediatric Drug Partnership
Certara® and Paidion Research, announced a new partnership to address the challenges inherent in pediatric drug development.
Advertisement
Certara®, a global biosimulation technology-enabled drug development company, and Paidion Research, a pediatric clinical research organization (CRO), announced a new partnership to address the challenges inherent in pediatric drug development including safe and effective dose or dose ranges and the conduct of trials. The partnership joins together Certara’s Simcyp® Pediatric PBPK simulator to inform the dose selections, with Paidon’s neonatal and pediatric intensive care unit and pediatric clinical site networks and clinical trials experience.
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Quantifying the Net Financial Value of Deploying Risk-Based Quality Management
2
ACT Brief: RBQM Financial Value Quantified, Sponsor-Configurable AI Systems, and Basket Trials for Rare Pediatrics
3
ACT Brief: Enterprise Risk Management, Execution Architecture for AI, and Rare Pediatric Regulatory Support
4
ACT Brief: Data Pipeline Fragmentation, Vaccine Trial Pressures, and BTK Degrader Partnership
5




